These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 30774318)

  • 1. Comparison of health-related quality of life in patients with rheumatoid arthritis during conventional or conventional plus biological therapy in Poland.
    Bąk E; Marcisz C; Borodzicz A; Sternal D; Krzemińska S
    Patient Prefer Adherence; 2019; 13():223-231. PubMed ID: 30774318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Nottingham Health Profile as a measure of disease activity and outcome in rheumatoid arthritis.
    Houssien DA; McKenna SP; Scott DL
    Br J Rheumatol; 1997 Jan; 36(1):69-73. PubMed ID: 9117179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of Biological Therapeutics on Patient-Reported Quality-Of-Life Outcomes (Whoqol-Bref), Functional Scores and Disease Activity among Croatian Patients with Rheumatoid Arthritis: Our Experience.
    Gudelj Gračanin A; Matić A; Mikula T; Dobša J; Žagar I; Mužinić Marinić L; Morović-Vergles J
    Psychiatr Danub; 2020 Nov; 32(Suppl 4):547-552. PubMed ID: 33212462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT.
    Strand V; Pope J; Tundia N; Friedman A; Camp HS; Pangan A; Ganguli A; Fuldeore M; Goldschmidt D; Schiff M
    Arthritis Res Ther; 2019 Dec; 21(1):272. PubMed ID: 31815649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission with Six Months of Biological DMARDs Treatment.
    Miwa Y; Takahashi R; Ikari Y; Maeoka A; Nishimi S; Oguro N; Hayashi T; Hatano M; Isojima S; Yanai R; Kasama T; Toyoshima Y; Inagaki K; Sanada K
    Intern Med; 2017; 56(8):903-906. PubMed ID: 28420837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Conventional and Biological Drugs Used for the Treatment of Rheumatoid Arthritis on the Quality of Life and Depression.
    Yayikci YI; Karadag A
    Eurasian J Med; 2019 Feb; 51(1):12-16. PubMed ID: 30911249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study.
    van Mulligen E; de Jong PHP; Kuijper TM; van der Ven M; Appels C; Bijkerk C; Harbers JB; de Man Y; Molenaar THE; Tchetverikov I; Goekoop-Ruiterman YPM; van Zeben J; Hazes JMW; Weel AEAM; Luime JJ
    Ann Rheum Dis; 2019 Jun; 78(6):746-753. PubMed ID: 30954969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The treatment of patients with elderly-onset rheumatoid arthritis at Niigata Rheumatic Center].
    Takai C; Kobayashi D; Ito S; Murasawa A; Wada Y; Narita I; Nakazono K
    Nihon Ronen Igakkai Zasshi; 2018; 55(2):251-258. PubMed ID: 29780094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial.
    van der Leeuw MS; Welsing PMJ; de Hair MJH; Jacobs JWG; Marijnissen ACA; Linn-Rasker SP; Fodili F; Bos R; Tekstra J; van Laar JM
    Trials; 2020 Apr; 21(1):313. PubMed ID: 32248829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of socio-demographic and clinical characteristics on functional disability and health-related quality of life in patients with rheumatoid arthritis: a cross-sectional study from Palestine.
    Al-Jabi SW; Seleit DI; Badran A; Koni A; Zyoud SH
    Health Qual Life Outcomes; 2021 Oct; 19(1):241. PubMed ID: 34645455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of treatment with the first TNF antagonist in monotherapy, the first TNF antagonist plus one conventional synthetic disease-modifying antirheumatic drug, and the first TNF antagonist plus two or more conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    Hernández-Cruz B; Márquez-Saavedra E; Caliz-Caliz R; Navarro-Sarabia F
    Arthritis Res Ther; 2016 Nov; 18(1):259. PubMed ID: 27821150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study.
    Ozen G; Pedro S; Schumacher R; Simon TA; Michaud K
    Arthritis Res Ther; 2019 Jun; 21(1):141. PubMed ID: 31174592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-Regression of a Dose-Response Relationship of Methotrexate in Mono- and Combination Therapy in Disease-Modifying Antirheumatic Drug-Naive Early Rheumatoid Arthritis Patients.
    Bergstra SA; Allaart CF; Stijnen T; Landewé RBM
    Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1473-1483. PubMed ID: 27992656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Nottingham Health Profile in rheumatoid arthritis: correlation with other health status measurements and clinical variables.
    Sivas F; Erçin O; Tanyolaç O; Barça N; Aydoğ S; Ozoran K
    Rheumatol Int; 2004 Jul; 24(4):203-6. PubMed ID: 12942312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis.
    Bergstra SA; Allaart CF; van den Berg R; Chopra A; Govind N; Huizinga TWJ; Landewe RBM
    Arthritis Res Ther; 2017 Nov; 19(1):258. PubMed ID: 29166919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unmet needs in the treatment of rheumatoid arthritis. An observational study and a real-life experience from a single university center.
    Kaltsonoudis E; Pelechas E; Voulgari PV; Drosos AA
    Semin Arthritis Rheum; 2019 Feb; 48(4):597-602. PubMed ID: 30075990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors.
    Strand V; Reaney M; Chen CI; Proudfoot CW; Guillonneau S; Bauer D; Mangan E; Graham NM; van Hoogstraten H; Lin Y; Pacheco-Tena C; Fleischmann R
    RMD Open; 2017; 3(1):e000416. PubMed ID: 28326189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.
    Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Ma M; Walker D; Heslin M; Patel A; Kingsley G
    Health Technol Assess; 2014 Oct; 18(66):i-xxiv, 1-164. PubMed ID: 25351370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fatigue and associated factors in a multi-ethnic cohort of rheumatoid arthritis patients.
    Lee HJ; Pok LSL; Ng CM; Yahya F; Sockalingam S; Tee YC; Raja J
    Int J Rheum Dis; 2020 Aug; 23(8):1088-1093. PubMed ID: 32597545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient-reported outcomes from a Phase 3 randomized controlled trial.
    Li Z; An Y; Su H; Li X; Xu J; Zheng Y; Li G; Kwok K; Wang L; Wu Q
    Int J Rheum Dis; 2018 Feb; 21(2):402-414. PubMed ID: 29314645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.